---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-050329"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2025-06-03T23:59:59+00:00"
generated_at: "2026-05-20T01:54:01.647411+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Estrella Immunopharma raises ~$3.35M in PIPE at $1.50/share

## Summary
- Issued 2,233,334 shares at $1.50 each (premium to $1.00 close on May 29, 2025).
- Net proceeds to fund Phase I STARLIGHT-1 trial of EB103 CD19-targeted T-cell therapy in NHL.
- True-Up provision: additional shares if 12-month closing price below $1.50 (floor $0.20).
- Company agreed to file resale registration statement for shares issued in PIPE.
- Closing subject to customary conditions; investor support cited as confidence in ARTEMIS platform.

## SEC filing metadata
- accession: 0001213900-25-050329
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2025-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390025050329/0001213900-25-050329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390025050329/ea0244428-8k_estrella.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-050329
- JSON: https://secwatch.observer/filing/0001213900-25-050329.json
- Plain text: https://secwatch.observer/filing/0001213900-25-050329.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.